Partnering opportunity

A French Technology Transfer Office offers a new adujvant which improves therapeutic vaccination.

Summary

A French Technology Transfer Office (TTO) offers a new adjuvant which improves therapeutic vaccination and more precisely the vaccines' immune response thanks to a patented micro-particle containing a new liposome. The French TTO is looking for interested pharmacology corporates or biotechnology SMEs, either for a licensing agreement or a technical cooperation agreement.

Partner sought

The partner sought could be a company involved in the vaccination domain -not only on RNA vaccine- interested in developing some more efficient therapeutic vaccines. A licensing agreement is open to manufacturing drugs firms which are able to drive pre-clinical testing of the new molecule, prior to its manufacturing and commercialization of the specific medicine for Papilloma Virus Human (PVH). A technical cooperation agreement may also interest companies in biotechnology which are interested to develop new RNA vaccines.

Description

A French TTO acting on behalf major life science research labs in Paris Region, has designed and synthetized a new patented micro-particle which strongly improves the efficacy of a type of vaccines: ribonucleic acid (RNA) vaccines. The proof of concept has been performed on Human Papilloma Virus (HPV) inoculated to mice, but this technology can be used for any kind of RNA vaccines (for infectious diseases and oncology) to treat both liquid and solid tumours such as breast or prostate cancers, HIV, tuberculosis… Vaccination (or active immunotherapy) consists in inserting a specific antigen linked to the pathogenic against whom the body has to be protected by stimulating the immune system. The innovation is based on the key role of liposomal vaccination. This innovative liposome is a particle formed by lipids and mannose motif which enclosed the antigen. This liposome targets immune cells (with adjuvant effect) which allows in situ antigen production, that is the reason of its protective effect. The partner sought could be a company interested in : - a license agreement as the TTO is ready to negotiate directly the patents rights for specific applications, or - a technical cooperation agreement The French TTO is able to provide technical and legal assistance to facilitate the eventual partnership

Advantages and innovations

The vaccination with this technology allows a better targeting of the immune cells. Indeed, currently the vaccines on the market are not completely efficient because the antigen is not always in contact with the immune cells due to to a specificity default. The advantages of this new technology are: - specifically targeting cells, dendritic cells in particular (by a optimization of activation of these cells) - ability to facilitate antigen presentation - protection of synthetic mRNA from its degradation - avoiding the use of foreign DNA in cells (because RNA is used) The vaccination with this technology improves the mouses survival of 30% compared to a classical vaccine approach

Development stage

Prototype available for demonstration

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company